相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。New Therapeutic Strategies for Adult Acute Myeloid Leukemia
Hiroto Ishii et al.
CANCERS (2022)
Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
David A. Sallman et al.
BLOOD (2021)
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML
Martin Wermke et al.
BLOOD (2021)
The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses
Rory M. Shallis et al.
BLOOD REVIEWS (2021)
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
Albert Oriol et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2021)
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19
Peter Braendstrup et al.
CYTOTHERAPY (2020)
A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Rebecca Epperly et al.
FRONTIERS IN ONCOLOGY (2020)
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
David A. Sallman et al.
BLOOD (2020)
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Matteo Libero Baroni et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
David A. Sallman et al.
BLOOD (2020)
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
Alexandre V. Hirayama et al.
BLOOD (2019)
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H. Baumeister et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Overcoming Target Driven Fratricide for T Cell Therapy
Eytan Breman et al.
FRONTIERS IN IMMUNOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Exploiting natural killer group 2D receptors for CAR T-cell therapy
Benjamin Demoulin et al.
FUTURE ONCOLOGY (2017)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
Caroline Lonez et al.
BMJ OPEN (2017)
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
Fabiana Perna et al.
CANCER CELL (2017)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
Saar Gill et al.
BLOOD (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Regulation of Ligands for the NKG2D Activating Receptor
David H. Raulet et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Mouse Tumor Vasculature Expresses NKG2D Ligands and Can Be Targeted by Chimeric NKG2D-Modified T Cells
Tong Zhang et al.
JOURNAL OF IMMUNOLOGY (2013)
Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment
Amorette Barber et al.
JOURNAL OF IMMUNOLOGY (2009)
Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer
Amorette Barber et al.
JOURNAL OF IMMUNOLOGY (2008)
Chimeric NKG2D-Modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways
Tong Zhang et al.
CANCER RESEARCH (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Roles of the NKG2D immunoreceptor and its ligands
DH Raulet
NATURE REVIEWS IMMUNOLOGY (2003)
分享论文
